Erythroderma with brentuximab vedotin in a patient with mycosis fungoides

Eur J Dermatol. 2023 Apr 1;33(2):167-168. doi: 10.1684/ejd.2023.4424.

Authors

Masakazu Kakurai¹, Kazumasa Oya¹, Shoichiro Ishizuki¹, Yasuhito Suehara², Toshifumi Nomura¹

Affiliations

¹ Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
² Department of Hematology, University of Tsukuba Hospital, Ibaraki, Japan.

PMID: 37431123
DOI: 10.1684/ejd.2023.4424

No abstract available

MeSH terms

Brentuximab Vedotin
Dermatitis, Exfoliative* / drug therapy
Dermatitis, Exfoliative* / etiology
Humans
Mycosis Fungoides* / complications
Mycosis Fungoides* / drug therapy
Skin Neoplasms* / complications
Skin Neoplasms* / drug therapy

Substances

Brentuximab Vedotin